Cited by 324Systemic Lupus Erythematosus ResearchVenous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis Mechanisms

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies

Ruiz‐Irastorza, Guillermo, Hunt, Beverley J., Khamashta, Munther A.·2007·Arthritis Care & Research

DOI 10.1002/art.23109

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To systematically review the efficacy and safety data of different therapeutic approaches in patients with antiphospholipid antibodies (aPL) and thrombosis. METHODS: The Medline database and references from selected reports and review articles were used. Randomized controlled trials, prospective and retrospective cohort studies, and subgroup analysis (n > 15) that focused on the secondary thromboprophylaxis in patients with aPL were selected. RESULTS: Sixteen studies were selected. Patients with venous events and a single test for aPL showed a low recurrence rate while receiving oral anticoagulation at a target international normalized ratio (INR) of 2.0-3.0. Patients with stroke and a single positive aPL test had no increased risk compared with those without aPL. Recurrence rates in patients with definite antiphospholipid syndrome (APS) and previous venous thromboembolism were lower than in patients with arterial and/or recurrent events, both with and without therapy. Only 3.8% of recurrent events occurred at an actual INR >3.0. Mortality due to recurrent thrombosis was higher than mortality due to bleeding (18 patients versus 1 patient reported). CONCLUSION: For patients with definite APS, we recommend prolonged warfarin therapy at a target INR of 2.0-3.0 in APS patients with first venous events and >3.0 for those with recurrent and/or arterial events. For patients with venous thromboembolism or stroke and a single positive aPL test, we recommend further testing to determine if they have a persisting antibody. If they do not, the same therapy as for the general population should be used (warfarin at a target INR of 2.0-3.0 and low-dose aspirin, respectively).

Integrity signals

Registry

Crossref · 10.1002/art.23109

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
Cervera, R., Piette, J., Font, J., Khamashta, M. A., Shoenfeld, Y., Camps, M. T., Jacobsen, S., Lakos, G., Tincani, A., Kontopoulou‐Griva, I., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10187 · Cited by 2,156
Antithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M. M., Tapson, V. F., & Weg, J. G. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,035
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)
Palareti, G., Leali, N., COCCHERI, S., Poggi, M., Manotti, C., D’Angelo, A., Pengo, V., Erba, N., Moia, M., CIAVARELLA, N., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01109-9 · Cited by 1,319
Antithrombotic Therapy for Venous Thromboembolic Disease
Büller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., & Raskob, G. E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.401s · Cited by 1,249
Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
Guyatt, G., Gutterman, D., Baumann, M. H., Addrizzo-Harris, D., Hylek, E. M., Phillips, B., Raskob, G., Lewis, S. Z., & Schünemann, H. (2006) · Chest · doi:10.1378/chest.129.1.174 · Cited by 1,220
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke
Mohr, J. P., Thompson, J. L. P., Lazar, R. M., Levin, B., Sacco, R. L., Furie, K. L., Kistler, J. P., Albers, G. W., Pettigrew, L. C., Adams, H. P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011258 · Cited by 1,168
Hemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G. E., Landefeld, S., & Kearon, C. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.108s · Cited by 1,129
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome
Crowther, M. A., Ginsberg, J. S., Julian, J., Denburg, J., Hirsh, J., Douketis, J., Laskin, C., Fortin, P., Anderson, D., Kearon, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035241 · Cited by 919

Flagged first, then by citations

Show all 40 references

Sorted by citations

Evidence-Based Management of Anticoagulant Therapy
Holbrook, A. M., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M. A., & Guyatt, G. H. (2012) · CHEST Journal · doi:10.1378/chest.11-2295 · Cited by 1,292
EULAR recommendations for the management of antiphospholipid syndrome in adults
Tektonidou, M. G., Andreoli, L., Limper, M., Amoura, Z., Cervera, R., Costedoat-Chalumeau, N., Cuadrado, M. J., Dörner, T., Ferrer-Oliveras, R., Hambly, K., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215213 · Cited by 1,318
Antiphospholipid syndrome
Ruiz‐Irastorza, G., Crowther, M. A., Branch, W. D., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 875
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task Force of the EULAR standing Committee for clinical Affairs
Bertsias, G. K., Ioannidis, J. P. A., Aringer, M., Bollen, E., Bombardieri, S., Bruce, I. N., Cervera, R., Dalakas, M., Doria, A., Hanly, J. G., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.130476 · Cited by 742
Guidelines on the investigation and management of antiphospholipid syndrome
Keeling, D., Mackie, I., Moore, G. W., Greer, I. A., Greaves, M., & British Committee for Standards in Haematology (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09037.x · Cited by 740
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task Force at the 13th International Congress on antiphospholipid antibodies
Ruiz-Irastorza, G., Cuadrado, M., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V, et al. (2011) · Lupus · doi:10.1177/0961203310395803 · Cited by 506
Antiphospholipid syndrome
Schreiber, K. I., Sciascia, S., de Groot, P. G., Devreese, K. M. J., Jacobsen, S., Ruiz‐Irastorza, G., Salmon, J. E., Shoenfeld, Y., Shovman, O., & Hunt, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.103 · Cited by 445
Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the “CAPS Registry”
Cervera, R., Bucciarelli, S., Plasín, M. Á., Gómez-Puerta, J. A., Plaza, J., Pons‐Estel, G., Shoenfeld, Y., Ingelmo, M., & Espinos, G. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.02.008 · Cited by 357
Guideline for investigation and management of adults and children presenting with a thrombocytosis
Harrison, C. N., Bareford, D., Butt, N. M., Campbell, P. J., Conneally, E., Drummond, M. W., Erber, W. N., Everington, T., Green, A. R., Hall, G. W., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08122.x · Cited by 317
Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial
Ordi-Ros, J., Sáez-Comet, L., Pérez-Conesa, M., Vidal, X., Riera-Mestre, A., Castro-Salomó, A., Cuquet-Pedragosa, J., Ortiz-Santamaria, V., Mauri-Plana, M., Solé, C., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0291 · Cited by 324
Diagnosis and management of neuropsychiatric SLE
Hanly, J. G. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.15 · Cited by 297
Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations
Bertsias, G. K., & Boumpas, D. T. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.62 · Cited by 283
Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management
Knight, J. S., Branch, D. W., & Ortel, T. L. (2023) · BMJ · doi:10.1136/bmj-2021-069717 · Cited by 299
Risk assessment for recurrent venous thrombosis
Kyrle, P. A., Rosendaal, F. R., & Eichinger, S. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60962-2 · Cited by 266
Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry
Avčin, T., Cimaz, R., Silverman, E. D., Cervera, R., Gattorno, M., Garay, S. M., Berkun, Y., Sztajnbok, F., Silva, C. A., Campos, L. M. A., et al. (2008) · PEDIATRICS · doi:10.1542/peds.2008-1209 · Cited by 246
Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives
Magro‐Checa, C., Zirkzee, E. J. M., Huizinga, T. W. J., & Steup‐Beekman, G. M. (2016) · Drugs · doi:10.1007/s40265-015-0534-3 · Cited by 244
Neuropsychiatric lupus: a mosaic of clinical presentations
Kivity, S., Agmon‐Levin, N., Zandman‐Goddard, G., Chapman, J., & Shoenfeld, Y. (2015) · BMC Medicine · doi:10.1186/s12916-015-0269-8 · Cited by 219
Management of the obstetric antiphospholipid syndrome
Derksen, R. H. W. M., Khamashta, M. A., & Branch, D. W. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20105 · Cited by 200
Antiphospholipid syndrome
Sammaritano, L. R. (2019) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.101463 · Cited by 211
Antiphospholipid Syndrome
Corban, M., Duarte‐García, A., McBane, R. D., Matteson, E. L., Lerman, L. O., & Lerman, A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.058 · Cited by 186
Does thrombophilia testing help in the clinical management of patients?
Middeldorp, S., & Vlieg, A. V. H. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07339.x · Cited by 177
The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS
McDonnell, T. C. R., Wincup, C., Buchholz, I., Pericleous, C., Giles, I., Ripoll, V. M., Cohen, H., Delcea, M., & Rahman, A. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100610 · Cited by 176
Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade
Bertsias, G. K., Salmon, J. E., & Boumpas, D. T. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.135186 · Cited by 152
The diagnosis and management of the haematologic manifestations of lupus
Velo-García, A., Castro, S. G., & Isenberg, D. A. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.07.001 · Cited by 165
Diagnosis of antiphospholipid syndrome in routine clinical practice
Gardiner, C., Hills, J., Machin, S., & Cohen, H. (2013) · Lupus · doi:10.1177/0961203312460722 · Cited by 131
In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of β2-glycoprotein I: proof of concept
Ioannou, Y., Penabad, Z. R., Pericleous, C., Giles, I., Papalardo, E., Vargas, G., Shilagard, T., Latchman, D. S., Isenberg, D. A., Rahman, A., et al. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03316.x · Cited by 130
Diagnosis and management of the antiphospholipid syndrome
Cohen, D. B., Berger, S. P., Steup‐Beekman, G. M., Bloemenkamp, K. W. M., & Bajema, I. M. (2010) · BMJ · doi:10.1136/bmj.c2541 · Cited by 127
Is Thrombophilia Testing Useful?
Middeldorp, S. (2011) · Hematology · doi:10.1182/asheducation-2011.1.150 · Cited by 125
Pathogenesis and management of antiphospholipid syndrome
Arachchillage, D. J., & Laffan, M. (2017) · British Journal of Haematology · doi:10.1111/bjh.14632 · Cited by 125
Persistent Antiphospholipid Antibody (APL) in Asymptomatic Carriers as a Risk Factor for Future Thrombotic Events: A Nationwide Prospective Study
Mustonen, P., Lehtonen, K. V., Javela, K., & Puurunen, M. (2014) · Lupus · doi:10.1177/0961203314545410 · Cited by 127
The antiphospholipid syndrome: from pathophysiology to treatment
Negrini, S. M., Pappalardo, F., Murdaca, G., Indiveri, F., & Puppo, F. (2016) · Clinical and Experimental Medicine · doi:10.1007/s10238-016-0430-5 · Cited by 117
Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment
Tripodi, A., de Groot, P. G., & Pengo, V. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02362.x · Cited by 114
The management of neuropsychiatric lupus in the 21st century: still so many unmet needs?
Govoni, M., & Hanly, J. G. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa404 · Cited by 113
Current treatment of antiphospholipid syndrome: lights and shadows
Espinosa, G., & Cervera, R. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.88 · Cited by 110
Antiphospholipid syndrome
Lim, W. (2013) · Hematology · doi:10.1182/asheducation-2013.1.675 · Cited by 107
Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults
Tektonidou, M. G., Andréoli, L., Limper, M., Tincani, A., & Ward, M. M. (2019) · RMD Open · doi:10.1136/rmdopen-2019-000924 · Cited by 101
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients
Schaefer, J. K., McBane, R. D., Black, D. M., Williams, L. N., Moder, K. G., & Wysokiński, W. E. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-03-0272 · Cited by 90
Neuropsychiatric Manifestations in Systemic Lupus Erythematosus
Postal, M., Costallat, L. T. L., & Appenzeller, S. (2011) · CNS Drugs · doi:10.2165/11591670-000000000-00000 · Cited by 94
Primary Adrenal Insufficiency Due to Bilateral Adrenal Hemorrhage-Adrenal Infarction in the Antiphospholipid Syndrome: Long-Term Outcome of 16 Patients
Ramon, I., Mathian, A., Bachelot, A., Hervier, B., Haroche, J., Huong, D. U. L. T., Costedoat-Chalumeau, N., Wechsler, B., Karmali, R., Velkeniers, B., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4300 · Cited by 91
Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management
Sayar, Z., Moll, R., Isenberg, D. A., & Cohen, H. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.10.010 · Cited by 113
Anti‐protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome
Arachchillage, D. J., Efthymiou, M., Mackie, I. J., Lawrie, A. S., Machin, S. J., & Cohen, H. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12722 · Cited by 86
Thrombosis in Systemic Lupus Erythematosus: A Review Article
Al-Homood, I. A. (2012) · ISRN Rheumatology · doi:10.5402/2012/428269 · Cited by 86
Venous Thrombosis in the Antiphospholipid Syndrome
Farmer-Boatwright, M. K., & Roubey, R. A. S. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.182204 · Cited by 82
Pediatric Antiphospholipid Syndrome
Cimaz, R., & Descloux, É. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.05.005 · Cited by 81
Management of antiphospholipid syndrome
Tuthill, J. I., & Khamashta, M. A. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.05.002 · Cited by 78
Neuropsychiatric Systemic Lupus Erythematosus Involvement: Towards a Tailored Approach to Our Patients?
Faria, R., Gonçalves, J., & Dias, R. (2017) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10276 · Cited by 77
Antiphospohlipid syndrome in obstetrics
Danza, Ã., Ruiz‐Irastorza, G., & Khamashta, M. A. (2011) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2011.10.006 · Cited by 74
Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment
de Amorim, L. C. D., Maia, F. M., & Rodrigues, C. E. M. (2017) · Lupus · doi:10.1177/0961203316688784 · Cited by 71
Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS)
Gebhart, J., Posch, F., Koder, S., Perkmann, T., Quehenberger, P., Zoghlami, C., Ay, C., & Pabinger, I. (2015) · Blood · doi:10.1182/blood-2014-11-611129 · Cited by 77
Ocular manifestations of the antiphospholipid syndrome
Utz, V. M., & Tang, J. C. O. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.182857 · Cited by 72
Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases
Signorelli, F., Nogueira, F., Domingues, V., Mariz, H. D. A., & Levy, R. A. (2015) · Clinical Rheumatology · doi:10.1007/s10067-015-3030-y · Cited by 71
New approaches for managing antiphospholipid syndrome
Erkan, D., & Lockshin, M. D. (2009) · Nature Reviews Rheumatology · doi:10.1038/ncprheum1017 · Cited by 71
Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome
Noël, N., Dutasta, F., Costedoat-Chalumeau, N., Bienvenu, B., Mariette, X., Geffray, L., Sène, D., Chaidi, R. B., Michot, J., Fain, O., et al. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.03.007 · Cited by 67
Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management—An Insight into Future Approaches
Chighizola, C. B., Ubiali, T., & Meroni, P. L. (2015) · Journal of Immunology Research · doi:10.1155/2015/951424 · Cited by 67
Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy
Jackson, W. G., Oromendia, C., Ünlü, O., Erkan, D., & DeSancho, M. T. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017008185 · Cited by 66
Antiphospholipid syndrome: frequency, main causes and risk factors of mortality
Espinosa, G., & Cervera, R. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.47 · Cited by 65
The treatment of anti-phospholipid syndrome: A comprehensive clinical approach
Chighizola, C. B., Andréoli, L., Gerosa, M., Tincani, A., Ruffatti, A., & Meroni, P. L. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.02.003 · Cited by 66
Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease
Brutto, V. J. D., Chaturvedi, S., Diener, H., Romano, J. G., & Sacco, R. L. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.06.039 · Cited by 71
“Non-criteria” antiphospholipid syndrome: A nomenclature proposal
da Rosa, G. P., Bettencourt, P., Rodríguez‐Pintó, I., Cervera, R., & Espinosa, G. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102689 · Cited by 64
Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach
Ambati, A., Knight, J. S., & Zuo, Y. (2023) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000932 · Cited by 68
Antiphospholipid syndrome
Khamashta, M. A., Taraborelli, M., Sciascia, S., & Tincani, A. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.04.002 · Cited by 66
Recent advances in the diagnosis and management of neuropsychiatric lupus
Legge, A. C., & Hanly, J. G. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01163-z · Cited by 66
An update on the management of antiphospholipid syndrome
Rodziewicz, M., & D’Cruz, D. P. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20910855 · Cited by 62
Demyelinating disease in SLE: Is it multiple sclerosis or lupus?
Checa, C. M., Cohen, D., Bollen, E. L. E. M., van Buchem, M. A., Huizinga, T. W. J., & Steup‐Beekman, G. M. (2013) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2013.07.010 · Cited by 57
Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study
Fischer-Betz, R., Specker, C., Brinks, R., & Schneider, M. (2012) · Lupus · doi:10.1177/0961203312451335 · Cited by 56
Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative
Coloma Bazán, E., Donate López, C., Moreno Lozano, P., Cervera, R., & Espinosa, G. (2013) · Immunologic Research · doi:10.1007/s12026-013-8407-x · Cited by 57
The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome
Malec, K., Góralczyk, T., & Undas, A. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.12.009 · Cited by 53
Management of refractory anti-phospholipid syndrome
Scoble, T., Wijetilleka, S., & Khamashta, M. A. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.04.030 · Cited by 53
Use of direct oral anticoagulants in antiphospholipid syndrome
Cohen, H., Efthymiou, M., & Isenberg, D. A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14017 · Cited by 69
Management of Recurrent Thrombosis in Antiphospholipid Syndrome
Nalli, C., Andréoli, L., Casu, C., & Tincani, A. (2014) · Current Rheumatology Reports · doi:10.1007/s11926-013-0405-4 · Cited by 43
Antiphospholipid syndrome: an update
Merashli, M., Noureldine, M. H. A., Uthman, I. W., & Khamashta, M. A. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12449 · Cited by 44
Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome
Efthymiou, M., Lawrie, A. S., Mackie, I. J., Arachchillage, D. J., Lane, P. J., Machin, S. J., & Cohen, H. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.03.030 · Cited by 43
Neuropsychiatric Lupus Erythematosus: Future Directions and Challenges; a Systematic Review and Survey
Yong-wen, Z., Han, H., & Chu, L. (2020) · Clinics · doi:10.6061/clinics/2020/e1515 · Cited by 41
High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: ‘PROS’ and ‘CONS’
Pengo, V., Ruiz‐Irastorza, G., Denas, G., Andréoli, L., Khamashta, M. A., & Tincani, A. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.10.016 · Cited by 40
Antiphospholipid syndrome: a clinical review
Mezhov, V., Segan, J., Tran, H. A., & Cicuttini, F. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50262 · Cited by 41
Antiphospholipid syndrome, antiphospholipid antibodies, and stroke
Mittal, P., Quattrocchi, G., Tohidi‐Esfahani, I., Sayar, Z., Chandratheva, A., & Cohen, H. (2022) · International Journal of Stroke · doi:10.1177/17474930221150349 · Cited by 41
Antiphospholipid syndrome in children
Avčin, T. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283060a8c · Cited by 38
Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome
Les, Í., Ruiz‐Irastorza, G., & Khamashta, M. A. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1304720 · Cited by 38
Systemic lupus erythematosus: An update for ophthalmologists
Papagiannuli, E., Rhodes, B., Wallace, G. R., Gordon, C., Murray, P. I., & Denniston, A. K. (2015) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.06.003 · Cited by 39
Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies
Watanabe, T., Oku, K., Amengual, O., Hisada, R., Ohmura, K., Nakagawa, I., Shida, H., Bohgaki, T., Horita, T., Yasuda, S., et al. (2017) · Lupus · doi:10.1177/0961203317716787 · Cited by 38
Platelets and Thrombotic Antiphospholipid Syndrome
Tohidi‐Esfahani, I., Mittal, P., Isenberg, D. A., Cohen, H., & Efthymiou, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030741 · Cited by 40
Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective
Pengo, V., & Denas, G. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.07.011 · Cited by 37
Management of Obstetric Antiphospholipid Syndrome
de Jesús, G. R., dos Santos, F. C., Oliveira, C., Mendes‐Silva, W., de Jesús, N. R., & Levy, R. A. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-011-0218-2 · Cited by 35
Management of Thrombotic Antiphospholipid Syndrome
Chighizola, C. B., Raimondo, M. G., & Meroni, P. L. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1597282 · Cited by 35
Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome
Ohnishi, N., Fujieda, Y., Hisada, R., Nakamura, H., Kato, M., Oku, K., Bohgaki, T., Amengual, O., Yasuda, S., & Atsumi, T. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key340 · Cited by 35
New oral anticoagulants in thrombotic antiphospholipid syndrome
Chighizola, C. B., Moia, M., & Meroni, P. L. (2014) · Lupus · doi:10.1177/0961203314540968 · Cited by 34
Epidemiology, characterization, and diagnosis of neuropsychiatric events in systemic lupus erythematosus
de Amorim, J. C., Frittoli, R. B., Pereira, D., Postal, M., Dertkigil, S. S. J., Reis, F., Costallat, L. T., & Appenzeller, S. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1564040 · Cited by 36
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management
Scheen, M., Adedjouma, A., Estève, E., Buob, D., Abisror, N., Planche, V., Fain, O., Boffa, J. J., de Seigneux, S., MEKINIAN, A., et al. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103072 · Cited by 36
Libman-Sacks endocarditis and associated cerebrovascular disease: The role of medical therapy
Roldan, C. A., Sibbitt, W. L., Greene, E. R., Qualls, C., & Jung, R. E. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247052 · Cited by 34
Domain I of β2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome
Ioannou, Y., & Rahman, A. (2010) · Lupus · doi:10.1177/0961203309360544 · Cited by 33
Antiphospholipid syndrome
Espinosa, G., & Cervera, R. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2536 · Cited by 33
Treatment of antiphospholipid syndrome
Radin, M., Cecchi, I., Rubini, E., Foddai, S. G., Barinotti, A., Menegatti, E., Roccatello, D., & Sciascia, S. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108597 · Cited by 32
Examining How Antiphospholipid Antibodies Activate Intracellular Signaling Pathways: A Systematic Review
Poulton, K., Rahman, A., & Giles, I. (2011) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2011.09.004 · Cited by 31
Diagnosis and treatment of antiphospholipid syndrome in childhood: A review
Rumsey, D. G., Myones, B. L., & Massicotte, P. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.02.009 · Cited by 30
The Antiphospholipid Syndrome
D’Cruz, D. P., & Khamashta, M. A. (2009) · Springer eBooks · doi:10.1007/978-1-84800-934-9_16 · Cited by 31
Towards evidence-based treatment of thrombotic antiphospholipid syndrome
Derksen, R. H. W. M., & de Groot, P. G. (2010) · Lupus · doi:10.1177/0961203309361483 · Cited by 30
Warfarin and the antiphospholipid syndrome: Does one size fit all?
Kasthuri, R. S., & Roubey, R. A. S. (2007) · Arthritis Care & Research · doi:10.1002/art.23111 · Cited by 30
Much more than thrombosis and pregnancy loss: The antiphospholipid syndrome as a ‘systemic disease’
Taraborelli, M., Andréoli, L., & Tincani, A. (2012) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2012.01.006 · Cited by 29
Diagnosis and therapy of antiphospholipid syndrome
Pengo, V., Denas, G., Jose, S. P., Zoppellaro, G., Bison, E., Banzato, A., Hoxha, A., & Ruffatti, A. (2015) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3051 · Cited by 28
Thrombotic recurrences and bleeding events in APS vascular patients: A review from the literature and a comparison with the APS Piedmont Cohort
Bazzan, M., Vaccarino, A., Stella, S., Bertero, M., CARIGNOLA, R., Montaruli, B., Roccatello, D., & Shoenfeld, Y. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.11.007 · Cited by 28

Authors: Ruiz‐Irastorza, G., Hunt, B. J., & Khamashta, M. A.
Affiliations: University of the Basque Country (ES)
St Thomas' Hospital (GB)
ORCID: Ruiz‐Irastorza, Guillermo
Hunt, Beverley J.
Khamashta, Munther A.
Venue: Arthritis Care & Research
Publisher: Wiley
Published: 2007-11-29
Volume: 57
Issue: 8
Pages: 1487-1495
ISSN: 0893-7524 (ISSN-L)
1529-0123
DOI: 10.1002/art.23109
OpenAlex: W2160198109
Cited by: 324
References: 40
Citations by year: 2026: 4 · 2025: 6 · 2024: 12 · 2023: 11 · 2022: 6 · 2021: 10 · 2020: 19 · 2019: 20 · 2018: 14 · 2017: 16 · 2016: 28 · 2015: 27 · 2014: 20 · 2013: 19 · 2012: 27
FWCI: 2.58
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Arthritis Care & Research (publishedVersion)
PubMed (publishedVersion)
Research Portal (King's College London) (submittedVersion)
Topics: Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords: antiphospholipid antibodies, antiphospholipid syndrome, warfarin, oral anticoagulation, international normalized ratio, venous thromboembolism, arterial thrombosis, stroke, recurrent thrombosis, bleeding risk, low-dose aspirin
MeSH terms: Anticoagulants, Aspirin, Humans, Platelet Aggregation Inhibitors, Thrombosis, Warfarin, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, International Normalized Ratio

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks